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Cancers, Osteosarcomas of the Jaw Bone, and Ovarian Cancers 
Abstract
In this project, I have done extensive research on two chemotherapy regimens, 
cisplatin/5-fluorouracil and cisplatin/Adriamycin. My hope is to compare and contrast 
the effectiveness of cisplatin-based regimens in the treatment of head and neck 
squamous cell carcinomas, osteosarcomas of the jaw, and ovarian cancers. In addition 
to literature searches, I have studied the medical files of two patients who were treated 
with cisplatin. One patient had recurrent, unresectable head and neck cancer and one 
patient has a resected, metastatic osteosarcoma of the mandible. After studying the 
case of the patient with head and neck cancer, I found exceptional results. After only 
one cycle of cisplatin/5FU, CT and PET scans showed no evidence of disease. I have 
concluded that cisplatin was effective in this case. As for the case of the patient with an 
osteosarcoma of the mandible, he showed mixed responses to cisplatin/Adriamycin. 
However, his responses to this regimen are much improved compared with his 
responses to his initial chemotherapy with a furosemide regimen. While on 
furosemide, his disease became metastatic, spreading to his lungs. Finally, my research 
on cisplatin-based chemotherapy for the treatment of ovarian cancer showed that other 
anti-cancer drugs, like docetaxel, may be more effective.
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In this project, I have done extensive research on two chemotherapy 
regimens, cisplatin/5-fluorouracil and cisplatin/Adriamycin. My hope is to 
compare and contrast the effectiveness of cisplatin-based regimens in the 
treatment of head and neck squamous cell carcinomas, osteosarcomas of the jaw, 
and ovarian cancers. In addition to literature searches, I have studied the medical 
files of two patients who were treated with cisplatin. One patient had recurrent, 
unresectable head and neck cancer and one patient has a resected, metastatic 
osteosarcoma of the mandible. After studying the case of the patient with head 
and neck cancer, I found exceptional results. After only one cycle of 
cisplatin/5FU, CT and PET scans showed no evidence of disease. I have 
concluded that cisplatin was effective in this case. As for the case of the patient 
with an osteosarcoma of the mandible, he showed mixed responses to 
cisplatin/Adriamycin. However, his responses to this regimen are much improved 
compared with his responses to his initial chemotherapy with a furosemide 
regimen. While on furosemide, his disease became metastatic, spreading to his 
lungs. Finally, my research on cisplatin-based chemotherapy for the treatment of 
ovarian cancer showed that other anti-cancer drugs, like docetaxel, may be more 
effective.
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Cisplatin-based Chemotherapy for Treatment of Head and Neck 
Cancers, Osteosarcomas of the Jaw Bone, and Ovarian Cancers 
Introduction:
Cancer is one of the most common causes of death in developed nations. 
One in five people in the United States and Europe will die due to cancer (Sai 
Man Liu, 1999). Most people will be affected in some way by this disease at 
some point in their lives. Although most people know someone who has been 
affected by cancer, many people do not actually understand the mechanism 
behind cancer or the drugs used to treat it. Many people mistakenly believe that 
cancerous cells are those cells that divide more rapidly than normal cells. This is 
simply a myth. The true difference between a normal cell and a cancerous cell is 
that cancerous cell division is unregulated or uncontrolled. Two other 
characteristics of a malignant cancer cell are that it is invasive, or capable of 
entering other tissues, and it is metastatic, which means that it can enter the blood 
or lymph, causing cancer to spread to other tissues or organs (Sai Man Liu, 1999). 
In addition to the myth about the definition of cancer, much is unknown about 
cancer treatment, especially the anti-cancer drug called cisplatin.
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General Discussion of Cisplatin:
My research began by studying the history, properties, and mechanism of 
cisplatin. Cisplatin is a widely used and effective chemotherapeutic agent. It 
belongs to a class called platinum-containing compounds (Sai Man Liu, 1999). 
Cisplatin’s role as an anti-cancer drug was first discovered in 1970. Its anti­
cancer capabilities were discovered purely by accident during research being done 
on E. coli using electric fields by Barnett Rosenberg and his colleagues. It was 
noticed during this research that the E. coli stopped dividing due to the electrodes, 
which were made of platinum (Sai Man Liu, 1999). After this, there were 
numerous studies done to see how effectively platinum compounds could stop cell 
division and how they could kill tumors. Of these platinum compounds, the cis 
isomer of diamminedichloroplatinum(II) (commonly called cisplatin) showed the 
best results as a possible anti-cancer drug in mice with leukemia. Clinical studies 
using cisplatin to treat cancers in humans soon followed, and it was eventually 
approved by the Food and Drug Administration in 1972. Early uses for cisplatin 
included treatments for both ovarian and testicular cancers. Its anti-cancer 
properties appeared to be the strongest in these two types of cancers. In one 
study, cisplatin, in combination with vinblastine and bleomycin, produced 
complete remission in 74% of testicular cancer patients (Sai Man Liu, 1999). 
Although its early uses were limited, cisplatin is now being prescribed to treat a 
wide variety of cancers. Some of these cancers include bladder cancer, gastric
Cisplatin-based Chemotherapy 5
cancer, head and neck cancer, lung cancer (non-small and small cell), 
osteosarcoma, and prostate cancer (BC Cancer Agency, 2006).
To study the effectiveness of cisplatin, one must first look at its properties. 
As already stated above, cisplatin is a platinum-containing compound. It is a 
planar compound with a central platinum atom. The platinum atom is covalently 
bonded to four other ligands, two ammonia groups and two chlorine atoms. The 




Structure of Diamminedichloroplatinum(II) (Cisplatin) 
(Miller, 2007)
To understand how cisplatin can prevent further cell division in malignant 
tumors and cancerous cells, one must look at its mechanism. First, cisplatin is 
able to gain entrance into the cell because of the concentration gradient that exists 
for chloride across the plasma membrane. The concentration of extracellular 
chloride is much higher than the internal cytoplasmic concentration of chloride. 
Therefore, because cisplatin is a chlorine-containing compound, cisplatin will
Cisplatin-based Chemotherapy 6 
naturally move into the cells as a result of this concentration gradient. Once 
inside the cell, two water molecules will attack the cisplatin molecule and 
displace the two chlorine atoms. This is an important step because this activates 
the cisplatin molecule as it becomes positively charged (BC Cancer Agency,
2006). The cisplatin molecule is then able to react with the DNA of the cells.
The DNA acts as a nucleophile and attacks the cisplatin molecule, displacing the 
water molecules, which are excellent leaving groups due to the fact that water is a 
weak base. Cisplatin specifically binds to the nitrogenous bases on the DNA 
creating inter and intra strand cross-links. These cross-links inhibit any further 
DNA replication, RNA transcription, or protein synthesis (translation), eventually 
resulting in programmed cell death. This cell death is called apoptosis (BC 
Cancer Agency, 2006).
Side Effects of Cisplatin:
Another important aspect of cisplatin to discuss before looking at its 
effectiveness against specific cancers is to look at why it causes side effects.
Also, I will discuss what specific side effects are associated with its use. Cisplatin 
is typically administered through an infusion or constant drip into the vein over a 
certain interval (Cancer Research UK, 2007). Immediately following these 
treatments, many patients experience a wide range of side effects.
The biological explanation for these side effects is actually quite simple. 
Cisplatin, like all other anti-cancer drugs, is not cell specific. This means that
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cisplatin is not specific to cancer cells, and is not capable of discriminating 
between normal and cancerous cells. There are a few exceptions to this rule. 
Sometimes anti-cancer drugs can recognize certain cell surface receptors, but for 
the most part, anti-cancer drugs are non-specific. In other words, cisplatin will 
attack and cause apoptosis in both normal and cancerous cells (Sai Man Liu, 
1999). For this reason, cisplatin causes a wide range of side effects because it 
also attacks normal cells.
Cisplatin’s effects are especially severe on types of cells that divide more 
often, such as the bone marrow, gastrointestinal epithelial cells, hair follicles, and 
the skin (Sai Man Liu, 1999). The most common side effects include thinning or 
brittle hair, loss of appetite, diarrhea, nausea and vomiting, taste alterations, and 
numbness in the hands and feet (Medline Plus, 2007).
Other serious side effects include kidney damage, hearing damage, and 
bone marrow effects (Cancer Research UK, 2007). Kidney damage is usually 
dose-dependent and is sometimes irreversible. In other words, the larger the dose 
of cisplatin, the more likely it is to damage the kidneys. Most of the damage is 
done to the cells of the proximal tubules in the nephron of the kidney (Sai Man 
Liu, 1999). Drinking plenty of water immediately after treatments is the main 
way to prevent this kidney damage. Medline Plus recommends drinking at least 
ten eight ounce glasses of water within the first twenty-four hours after treatment 
(Medline Plus, 2007). Hearing damage usually results in a ringing in the ears and
partial high-pitch hearing loss. Sometimes this damage is irreversible (Cancer 
Research UK, 2007).
The effects on the bone marrow can cause many symptoms. The decrease 
in the number of white blood cells increases the risk of infection. For this reason, 
patients on cisplatin should not receive immunizations while on cisplatin or be 
around people who have received oral immunizations. Bone marrow effects 
caused by cisplatin can also result in anemia and fatigue due to low red blood cell 
count. Finally, a drop in the function of the bone marrow can result in decreased 
ability to clot blood and more frequent bruising due to a decrease in the number of 
platelets (Cancer Research UK, 2007). Another very serious risk of taking 
cisplatin is developing a secondary cancer because cisplatin has been shown to be 
both an anti-cancer drug and a carcinogen, which means that it can also cause 
other types of cancers. In studies on female mice, cisplatin was shown to cause 
an increase in lung cancer (BC Cancer Agency, 2006). Its possible carcinogenic 
properties have not yet been proven in humans, however.
Although cisplatin is a powerful anti-cancer drug by itself, it is more 
potent in combination with other chemotherapeutic agents, especially in 
combination with 5-fluorouracil (5FU). The reason for this is because in 
combination, tumor cells are less likely to develop drug resistance to cisplatin. 
Also, the cisplatin/5FU combination has proven to have synergistic effects. This 
means that the effect of the two anti-cancer drugs in combination is much greater 
than would be expected if one simply added the effects that each drug has alone.
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General Discussion of 5-fluorouracil (5FU):
5-fluorouracil (5FU) belongs to a group of chemotherapy medications 
called anti-metabolites. This group of compounds is so named because they 
interfere with DNA repair and stop cells from making new DNA (Cancer 
Research UK, 2007). It is much like a cell nutrient, so cancer cells will naturally 
take 5FU into the cell (Medline Plus, 2007). 5FU specifically acts by stopping the 
functioning of an enzyme called thymidylate synthase, which is needed for DNA 
replication (Wikipedia, 2007). 5FU has been used as an anti-cancer drug for forty 
years, which is similar to the time of discovery of cisplatin. 5FU shows its best 
results in patients who have pancreatic and colorectal cancers (Wikipedia, 2007). 
However, it also shows effectiveness as an anti-cancer drug against breast, head 
and neck, gastric, and some skin cancers (Cancer Research UK, 2007). In 
combination with cisplatin, it can also be used for a few other types of cancer.
Like cisplatin and other anti-cancer drugs, 5FU’s action is non-specific.
Therefore, it does not discriminate between normal and cancerous cells.
Thus, there are a wide range of side effects associated with taking 5FU. 
They include thinning or brittle hair, headache, weakness, fatigue, diarrhea, dry 
skin, mouth sores, loss of appetite, numbness in the hands and feet, and bone 
marrow effects (Medline Plus, 2007). Another rare, but possible side effect of 
5FU is GI bleeding. If especially severe, the patient can require blood 
transfusions. As I will discuss below, the patient I studied who had recurrent,
unresectable head and neck cancer and was treated with the cisplatin/5FU 
regimen, experienced severe GI bleeding that required hospitalization. In fact, it 
put him in intensive care, and he almost died. 5FU was most likely the cause for 
this severe side effect. Despite the possible side effects that can sometimes be 
especially severe, cisplatin-based regimens can be very effective anti-cancer 
drugs. However, their effectiveness varies with the type of cancer they are 
treating. In the remainder of this paper, I will compare and contrast the 
effectiveness of cisplatin-based chemotherapies using both literature and actual 
patient case studies. I will begin with a discussion of a patient with head and neck 
cancer who I researched extensively.
Case Study 1 (Cancer Center Medical Files, 2006):
Exceptional Results of Treatment of Recurrent, Unresectable Squamous Cell 
Carcinoma of the Head and Neck with Only One Cycle of Cisplatin and 5FU 
Combination:
The patient is a 66-year-old male with a history of tobacco and alcohol 
use. The patient discovered a bump under his tongue in 2001, and a biopsy 
revealed grade I squamous cell carcinoma. The staging was T2N0MX. Stage II 
squamous cell carcinoma is between two and four centimeters in size, and has not 
spread from the oropharynx (National Cancer Institute, 2005). In April 2001, he 
had an anterior marginal mandibulectomy and bilateral selective neck dissections 
to remove a squamous cell carcinoma from the anterior floor of the mouth.
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However, in December 2002, the patient noticed a lump on the right side 
of his neck. Fine needle aspiration revealed recurrent squamous cell carcinoma of 
the head and neck. The carcinoma was very close to the carotid artery, so it was 
determined that the patient was not a surgical candidate. The plan was for the 
patient to undergo chemotherapy and subsequent radiation therapy. The patient 
was concerned about concurrent chemotherapy-radiation treatment.
Chemotherapy was with cisplatin at units of 100 mg/m and 5FU at units of 1000 
mg/m for five days of continuous infusion each week for three weeks. The 
patient experienced severe mucositis and dehydration with difficulty swallowing 
and pain in the mouth after the first round of treatment. The patient was admitted 
to Kishwaukee Community Hospital with GI bleeding and hypotension. The 
patient’s condition improved after receiving four units of red blood cells. A 
colonoscopy revealed a cecal mass consistent with a grade 3 adenocarcinoma.
The patient did not follow up for any chemotherapy or radiation as recommended. 
He did not finish the final two cycles of cisplatin; he completed only one cycle of 
chemotherapy prior to his hospitalization. Since he was so sick after the first 
round of chemotherapy, the patient declined any further chemotherapy or 
radiation.
Eight months after the patient’s hospitalization, he returned for a follow- 
up. An MRI of the neck and a PET scan did not reveal any signs of cancer. In 
October 2004, another PET scan came back negative, with no glucose uptake. 
There was no recurrence of head and neck cancer or colorectal cancer. The
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patient stated that even if the cancer recurred, he would not undergo any further 
treatment. By December 2005, the PET scan still showed no evidence of disease.
For more than three years there has been no evidence of recurring head 
and neck cancer or colon cancer. The patient completed only one cycle of 
chemotherapy and no radiation therapy, and yet, he has remained disease free.
The first cycle of chemotherapy ended up putting the patient in the Intensive Care 
Unit, but it was effective, eliminating the disease.
Discussion:
The standard of care for head and neck cancer in stage II has been surgery 
or radiation treatment (National Cancer Institute, 2005). In this case, the patient 
did not undergo any adjuvant chemotherapy-radiation after he underwent the 
anterior marginal mandibulectomy. Studies refute any added benefit of adjuvant 
chemoradiation combined with surgery for a resectable squamous cell carcinoma. 
In a clinical trial, the effectiveness of cisplatin-based neoadjuvant chemotherapy 
was tested. Nine patients underwent one cycle of chemotherapy, with cisplatin, 
docetaxel, and 5FU before undergoing the resection. Eighteen other patients who 
had surgery and no adjuvant chemotherapy were used as a control group. After 
three years, the survival rate of the group undergoing adjuvant chemotherapy was 
only 29.6%, whereas, the control group had an 81.57% three-year survival rate 
(Umeda, Komatsubara, & Ojima, 2004). These results showed that
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cisplatin-based neoadjuvant chemotherapy showed no benefits over the typical 
surgical treatment of resectable squamous cell carcinoma.
When the patient was diagnosed with recurrent squamous cell carcinoma 
in 2002, he was deemed inoperable because of the close proximity of the tumor to 
the carotid artery. The patient was to undergo both chemotherapy and radiation 
treatments, which is the standard of care for recurrent unresectable stage II head 
and neck cancer (National Cancer Institute, 2005). The benefits of this treatment 
plan have been shown in several clinical trials.
In a 1997-2002 study of 163 patients with unresectable pharyngeal 
carcinoma, the survival rates of patients who underwent only radiation (1.2 
Gy/day) versus patients who underwent adjuvant radiation (1.2 Gy/day) and
9 9chemotherapy with cisplatin (100 mg/m )/5FU(750 mg/m /day x 5 days) were 
tested. After 24 months, the overall survival rate of patients receiving the 
chemoradiation treatment was 37.8%; whereas, it was 20.1% with radiation alone 
(Bensadoun, Benezery, & Dassonville, 2006). The survival rates reflect the added 
benefits of chemoradiation in treating unresectable squamous cell carcinoma, 
specifically with cisplatin and 5FU.
A 2000 study on thirty-five patients with unresectable head and neck 
cancer also showed the benefits of receiving both chemotherapy and radiation 
simultaneously. Cisplatin was given to these patients for 5 days each week at a 
dose of 3 mg/m and 5FU was given continuously for five days each week at a
'y
dose of 150 mg/m . The radiation treatment was a total dosage of 60 Gy.
Cisplatin-based Chemotherapy 13
Cisplatin-based Chemotherapy 14
Seventy-nine percent of the patients in this study responded favorably to this 
concurrent treatment option. Nine of the patients remained completely disease 
free after receiving this treatment. Because of these results, it was concluded in 
this study that the concurrent chemoradiotherapy treatment can produce positive 
results for patients with unresectable head and neck cancer (Kohno, Kitahara, & 
Tamura, 2000).
In a 1996-2000 study with many patients who were already Stage IV for 
unresectable head and neck cancer, concurrent radiation and chemotherapy with 
cisplatin and 5FU proved effective. The dosages of cisplatin and 5FU were the 
same as the above study and the radiation was given at a total dosage of 68 Gy. 
Ninety percent of the patients in the study were stage IV for the disease. Yet, 
80% of the patients in the study responded favorably to the treatment, with either 
a complete or partial response. The median survival was twenty-three months 
with this treatment. Thus, it was concluded that adjuvant chemotherapy and 
radiation is also an effective treatment for patients with advanced stage IV 
unresectable head and neck cancer (Kohno, Kitahara, & Tamura, 2002).
In a three-year trial, thirty-six patients (eighteen with locally recurrent 
disease) underwent chemotherapy with paclitaxel (175 mg/mq) and cisplatin (75 
mg/mq) combination. The overall percentage of responders to the treatment was 
41.1%. The median overall survival time was eleven months, with four patients 
still alive, according to statistical evaluation (Adamo, Ferraro, Pergolizzi, 2004). 
The results of the study led to the conclusion that the paclitaxel and cisplatin
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combination is an effective and acceptably safe treatment for unresectable 
squamous cell carcinoma of the head and neck. This study showed that the 
paclitaxel and cisplatin combination has benefits similar to the cisplatin/5FU 
regimen; yet, it proved less toxic. The patient in this case experienced some of 
the toxic effects of the cisplatin/5FU regimen. He suffered severe mucositis and 
GI bleeding as a result of treatment with only one cycle of cisplatin and 5FU. 
After this response to the treatment, the patient had no further treatments, but has 
been disease free for over three years. This provides further evidence for the 
effectiveness of the cisplatin and 5FU regimen for unresectable, recurrent stage II 
squamous cell carcinoma of the head and neck.
In a study done in Chicago at Rush Medical College, seventy-eight 
patients with advanced head and neck cancer were studied over an eight year 
period to show how much more effective concurrent cisplatin/5FU therapy and 
radiation therapy was than cisplatin/5FU therapy followed by radiation therapy. 
The seventy-eight patients had either stage III or stage IV cancer. The five year 
survival rate was an incredible sixty percent with the concurrent cisplatin/5FU 
therapy. This is exceptional for patients with stage III and stage IV head and neck 
squamous cell carcinoma. In fact, of the sixteen patients with stage III cancer, 
none had any further progression. After eight years, 43% of the patients had 
survived. The best results were seen in patients with tongue and glottic cancers. 
The study concluded that the concurrent chemotherapy and radiation treatment
was very effective, especially since none of these patients had surgical resections 
(Taylor et al., 1997).
Case Study 2 (Cancer Center Medical Files, 2007): 
Cisplatin-Based Chemotherapy for an Osteosarcoma of the Jaw Bone:
A cisplatin-based regimen proved very effective for the treatment of a 
patient with recurrent, unresectable head and neck cancer. Cisplatin is also 
commonly used for osteosarcomas, otherwise known as bone cancers. I did some 
literature searches on this topic, finding only one study. This is not surprising, as 
osteosarcomas of the jaw are very rare. However, this study speaks volumes for 
the effectiveness of cisplatin in treating this disease. I was also able to find a 
patient at the Cancer Center where I volunteer with this condition who was 
willing to let me study his medical chart. My observations of his treatment with 
cisplatin have been summarized.
Ongoing Treatment with Cisplatin and Adriamycin in a Patient with a 
Resected, Metastatic Osteosarcoma of the Mandible:
The patient is a thirty-three year old Caucasian male, with no history of 
tobacco use and a history of leukemia in his family. Other social and family 
history is unremarkable. After complaining of jaw pain in January 2006, a whole 
body bone scan and spot views of the mandible were done. The bone scan 
revealed severe isotope accumulation in the right ramus of the mandible and in
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the anterior portion of the left ramus of the mandible. Tissues samples were taken 
two days later, and the pathologist confirmed the diagnosis of a low grade 
fibromyxoid sarcoma and osteosarcoma of the mandible.
After diagnosis, the patient underwent a subtotal mandibulectomy in 
February 2006. The entire right ramus of the mandible was removed up to the 
angle of the bone. The left ramus was only partially removed. It was removed 
anterior to the mental foramen. A bone graft was done with bone from the fibula 
in the leg. After the surgical resection, the patient underwent radiation therapy for 
two months, completing the treatment in April 2006. However, a CT scan of the 
neck done in April 2006 revealed asymmetric tissue in the tongue and oropharynx 
that indicated that the disease must have progressed.
At this point, it was recommended that the patient undergo subsequent 
chemotherapy. Since that time, the patient has been treated with three different 
chemotherapy regimens. He was started on a regimen which consisted of 
furosemide, Adriamycin, and methotrexate. After developing leucocytes, he 
stopped taking the methotrexate. However, he continued taking Adriamycin and 
furosemide. The patient did not respond as well as was hoped to this 
chemotherapy regimen. In August 2006, a CT scan of the chest showed many 
parenchymal and pleural nodules in the lungs. This proved that the cancer was 
now metastatic and had spread to the lungs. A needle biopsy of the right upper 
lobe of the lung confirmed that the disease was metastatic. The cells were
Cisplatin-based Chemotherapy 17
described as poorly differentiated, malignant, and very similar to the cells that 
were found in the mandible.
After discovering that the disease was metastatic, the patient discontinued 
his chemotherapy treatment with Adriamycin and furosemide. He was then 
placed on a cisplatin and Adriamycin regimen to see if there would be better 
results. He was placed on a dose of 45 mg of Adriamycin by infusion over a 
twenty-four hour period for three straight days, and he was placed on a dose of 
120 mg/m of cisplatin with magnesium sulfate and mannitol over an hour period 
on day one of treatment. He was recommended to undergo three cycles of this 
treatment. The patient initially had a mixed response to the new treatment. In 
November 2006, a Maxillofacial CT scan revealed a “moth-eaten” pattern on the 
anterior part of the remaining left ramus. The asymmetric tissue on the tongue 
and oropharynx, however, was no longer observed. The CT scan indicated that 
there may be recurrent disease. A chest CT scan done in November 2006 
revealed that the metastatic disease in the parenchyma in the lungs had also 
worsened. However, in December 2006, a chest CT scan indicated that although 
there were some new nodules in the lungs, most of the nodules had decreased in 
size. Another chest CT scan done in late January 2007 also showed mixed 
responses to the chemotherapy treatment, with the bilateral pulmonary nodules 
decreasing in size, but with the pleural tissue mass in the medial part of the base 
of the right lung increasing in size.
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In the last two months, however, the cisplatin-based regimen has produced 
much improvement in the metastatic disease. An April 2007 CT scan of the chest 
revealed a large decrease in the size of the pleural tissue mass in the right lower 
lobe, and there did not appear to be any new nodules in the lungs either. The 
patient has also been tolerating the treatments with cisplatin rather well. He has 
had some trouble keeping his potassium levels high enough. After developing 
this hypokalemia, he was prescribed potassium supplements to take three times 
daily. He was not very compliant at taking this medication and was hospitalized 
in January 2007 to get potassium supplements. At an appointment in March, he 
was still struggling with hypokalemia and hypomagnesia, but promised to start 
taking his potassium and magnesium supplements as prescribed.
The patient continues his ongoing chemotherapy treatment. Whether the 
osteosarcoma of the mandible or the metastatic disease in the lungs will recur is 
unknown; however, the last two months have shown that the cisplatin-based 
regimen has produced improvement in the patient’s condition. His metastatic 
disease now appears to be under control. I will have to continue to follow this 
case to see the long-term results of a cisplatin-based treatment for a resected 
osteosarcoma of the mandible with metastatic disease. I have also done literature 





In a study done at the Kidwai Memorial Institute of Oncology in India, 
only eight cases of osteosarcomas of the jaw bone were treated over a span of 
seven years. Four cases were cancer of the mandible bone and four cases were 
cancer of the maxilla bone. Three of these patients (two with cancer of the 
mandible and one with cancer of the maxilla) underwent surgery and subsequent 
six cycles of chemotherapy with cisplatin. All survived and were disease free 
four and a half years after the treatment commenced. The other five patients seen 
at this institute either did not finish the recommended treatment or elected to 
undergo no treatment at all electing to have only palliative care instead. Palliative 
care is aimed at reducing pain and making the patient more comfortable as 
opposed to actually treating the disease. All five of the patients that did not 
complete the treatment died within two years of diagnosis. This study is 
incredibly important in that it shows the effectiveness of a cisplatin-based 
treatment for osteosarcomas of the jaw for both the mandible and maxillary 
bones. This treatment obviously shows that cisplatin was the key element that 
determined a patient’s chance of survival (Doval et al., 1997).
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Results of Cisplatin-based Chemotherapy for Advanced Ovarian 
Carcinomas and the Impact of Intraperitoneal Chemotherapy:
Over thirty years ago, cisplatin was first approved by the Food and Drug 
Administration. At that time, it was only approved for the treatment of testicular 
and ovarian cancers. Its effects against other cancers were not yet proven at that 
time. Thus, when I began this project, I thought cisplatin would prove most 
effective against ovarian cancer. After doing literature searches, I have seen that 
this is not necessarily the case. In one study done at Jikel University School of 
Medicine in Tokyo, Japan, a twenty-four year old patient with a recurrent small 
cell ovarian carcinoma saw much better results using a docetaxel chemotherapy 
regimen as opposed to cisplatin. The patient received chemotherapy with 
cisplatin and etoposide after an initial surgery. However, the disease later 
recurred. After recurrence, the patient underwent chemotherapy with docetaxel 
and subsequently went into remission. The patient has now been disease free for 
more than two years (Niimi, Kiyokawa, Takakura, Ochiai, & Tanaka, 2006). A 
potential reason why cisplatin is not always an effective anti-cancer drug for small 
cell ovarian carcinomas is due to drug resistance. There is much speculation over 
how the ovarian cancer cells have developed this drug resistance. Some 
researchers have linked the resistance to phosphorylation of ERK2 by a kinase, 
which leads to activation of the ERK2 and subsequently, the cell becomes
resistant to the effects of cisplatin (Lee, Yoon, & Kim, 2007). Other researchers 
link cisplatin-resistance in small cell ovarian carcinomas to the cancer cell’s 
mitochondrial DNA, which does not as readily form cross-links with the cisplatin 
molecule. Without forming these cross-links, cisplatin can not induce apoptosis 
of the cell (Hirama, Isonishi, Yasuda, & Ishikawa, 2006).
While doing literature searches on the chemotherapy treatments for 
ovarian cancer, I found a great deal of literature concerning intraperitoneal (IP) 
chemotherapy. IP chemotherapy is administered directly into the abdomen rather 
than being administered by a drip into the vein (intravenous administration). IP 
chemotherapy has been shown to be much more effective at treating ovarian 
cancer. A review of three large Phase III trials studying the benefits of IP 
administration of a cisplatin-based chemotherapy regimen showed marked 
increases in survival with this type of treatment as opposed to the traditional 
intravenous treatment option. One trial showed an eight month increase in 
survival, another was eleven months, and the final trial was a sixteen month 
increase. The side effects associated with IP chemotherapy, however, were more 
severe than with intravenous chemotherapy, so there is a trade-off (Elit et al.,
2007). Despite these side effects, more attention should be paid to this type of 
chemotherapy for its obvious benefits.
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Cisplatin and Birth Defects:
One final issue I would like to highlight as a result of my research on 
cisplatin-based treatment of ovarian cancer is whether cisplatin can be safely 
administered during pregnancy. Although this is not typically a concern for most 
patients with ovarian cancer since the disease usually has a later onset, there are 
some patients who are diagnosed with the disease as teenagers or in their early 
twenties. For this reason, cisplatin has been studied for its potential to cause birth 
defects and to see how it would affect a developing fetus. All the articles I have 
read recommend that a woman not get pregnant while taking cisplatin. The larger 
issue, however, is what to do in the case of a woman who is diagnosed with 
ovarian cancer after she is already pregnant. This is a controversial topic.
However, I did find a published case study on a woman who was 
diagnosed with ovarian cancer during pregnancy. She elected to begin 
chemotherapy with cisplatin, vinblastine, and bleomycin when she was eighteen 
weeks into her pregnancy. A healthy baby was bom at thirty-one weeks with no 
birth defects. The mother experienced a secondary cancer to the liver five months 
later. However, it was treated with chemotherapy, and she remains disease free 
sixty-five months later (Motegi, Takakura, Takano, Tanaka, & Ochiai, 2007).
This is an isolated case, but the results give hope to expectant mothers who are 




After completing my extensive research on the numerous aspects of 
cisplatin-based chemotherapy, I have learned a great deal about the field of 
Oncology. This is a specialty I am very interested in pursuing after I complete 
medical school at the Medical College of Wisconsin in May 2011. On a broad 
level, I have seen that the field of Oncology is constantly evolving and changing. 
For instance, in thirty years, cisplatin has gone from a little known compound to a 
very effective chemotherapeutic agent, capable of treating a wide variety of 
cancers. After completing numerous literature searches and completing two case 
studies on patients, I have drawn a few conclusions about cisplatin-based 
treatments. The Cisplatin/5FU combination is very effective at treating recurrent 
head and neck cancer. Despite the severity of this type of cancer, remission 
becomes more likely with this type of chemotherapy, especially in combination 
with surgery, radiation therapy, or both. In the patient I studied with head and 
neck cancer, he showed remarkable and often rare results. One cycle of 
chemotherapy hit him so hard that he was placed in intensive care; yet, it proved 
effective. All subsequent PET and CT scans showed absolutely no evidence of 
disease. This is truly a remarkable case.
Osteosarcomas of the jaw bone are also very rare types of cancers. Yet, 
chemotherapy with a cisplatin-based treatment was shown to be the crucial 
element for survival in patients in one study. This study further illustrates the 
wide variety of effective uses for this platinum-containing anti-cancer drug.
Although the patient who I studied showed mixed responses to the initial 
treatment, his metastatic disease has been under control recently. His long-term 
response remains to be seen; however, it is clear that he has responded much 
better to the cisplatin regimen than to the furosemide regimen.
Studies on ovarian cancer, one of the first types of cancers treated with 
cisplatin chemotherapy regimens, have shown uncertain results for the 
effectiveness of a cisplatin-based treatment. Drug resistance appears to be the 
major source of concern. I wish I had been able to gain access to the medical file 
of a patient with ovarian cancer treated with cisplatin to further look at this. 
Possibly, I will be able to do this in the future. I am still very interested in this 
topic, and I believe more research can be done. My hope is to further study 
Oncology and Hematology in medical school because the future of cancer 
research and treatment seems to be filled with many possibilities and will likely 
result in many monumental discoveries. And hopefully, future discovery will 
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